Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3945 - Progressing G1-G2 neuroendocrine tumors (WD NET) in treatment with capecitabine (Cp) plus somatostatin analog (SSA): a single center experience


08 Oct 2016


Poster Display


Riccardo Marconcini


Annals of Oncology (2016) 27 (6): 136-148. 10.1093/annonc/mdw369


R. Marconcini1, S. Ricci2, L. Galli1, A. Antonuzzo2, C. Orlandini1, E. Vasile1, A. Falcone1

Author affiliations

  • 1 U.o. Oncologia Medica 2 Universitaria, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT
  • 2 U.o. Oncologia Medica 1 Ospedaliera, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT


Abstract 3945


Recently, Cp and Temozolamide (Tz) treatment has been investigated in NET in several studies, with heterogeneous populations and outcomes. Cp plus Tz reported a median PFS of about 13 months and it seems more efficient in pancreatic NET. Results from phase II and non-randomized trials with fluoropyrimidine in combination with SSA in well-differentiated (WD) NET are limited, and considered investigational. We review our experience in metastatic WDNET patients (pt) treated with only Cp and SSA, in order to identify eventual subgroups that may benefit from this treatment in terms of efficacy and tolerability.


From October 2005, 40 WDNET pt with progressive disease after failure of SSA and/or Everolimus, PRRT, other Chemotherapy, were treated with Cp and SSA. The primary tumors site was pancreas (P) in 17 pt, intestine (I) in 13 pt, lung (L) in 6 pt, and unknown (U) in 4 pt. Pt received Cp 1000 mg/mq/bidie days 1-14 and SSA (octreotide LAR 30mg 1 fl im q28 or lanreotide LAR 120mg 1 fl im q28). Treatment efficacy was evaluated by response rate according to RECIST criteria and in terms of Progression Free Survival (PFS). Safety and tolerability were evaluated following CTCAE v4 criteria.


Seven pt (17,5%%) had a Partial Response, 17 pt (42,5%) showed Stable Disease, 16 (40%) pt showed Progrssive Disease; median PFS was 6,1 (1-72,2+) months, 3 pt are still on treatment. In I-NET median PFS was 25,3 (2,2-70,8+)months: in particular G1 I-NET and G2 I-NET mPFS was 46,2 (13,5-70,8+) months and 4,3 (2,2-5,5+) months respectively. In P-NET median PFS was 7,3 (2,0-72,2+)months: in particular G1 P-NET and G2 P-NET mPFS was 7,5 (2,0-72,2+) months and 6,1 (2,5-34,0) months respectively. In L NET median PFS was 5,4 (1,4-6,6) months, in U NET it was 2,3 (1,0-11,6) months. At a median follow-up of 40 months, median OS was 48,7 (2,43-85,7+) months. Reported G1-G2 toxicities were diarrhea, nausea, asthenia; G3-G4 toxicities were not reported.


Cp plus SSA showed interesting activity and efficacy in pretreated pt with progressive WDNET with acceptable toxicity. In particular, G1 I-NET pt showed particular prolonged mPFS and in this group Cp plus SSA seems a valid therapeutic option.

Clinical trial identification

Legal entity responsible for the study

Azienda Ospadaliera Universitaria Pisana


Medical Oncology Department Pisa


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings